Product Description: Elacestrant (RAD1901) dihydrochloride is an orally available and selective estrogen receptor degrader (SERD) with IC50s of 48 and 870 nM for ERα and ERβ, respectively. Elacestrant dihydrochloride also can inhibit growth of ER+ breast cancer cell lines in vitro and in vivo[1][2].
Applications: Cancer-programmed cell death
Formula: C30H40Cl2N2O2
Citations: Cancer Discov. 2023 Nov 20./J Med Chem. 2020 Oct 8;63(19):11085-11099./Mol Cancer Ther. 2020 Jul;19(7):1395-1405./Biomed Pharmacother. 2024 Oct 14:180:117523./bioRxiv. 2023 Nov 2./bioRxiv. 2024 Jun 2:2024.05.28.596307./Harvard University. 2023 Mar. 30487357./J Cell Mol Med. 2023 Aug 18./NPJ Breast Cancer. 2022 Dec 14;8(1):130./Res Sq. 2024 Jun 04./Research Square Preprint. 2023 May 9./Research Square Preprint. 2024 Nov 06.
References: [1]Garner F, et al. RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models. Anticancer Drugs. 2015 Oct;26(9):948-56./[2]Bihani T, et al. Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models. Clin Cancer Res. 2017 Aug 15;23(16):4793-4804.
CAS Number: 1349723-93-8
Molecular Weight: 531.56
Compound Purity: 99.72
Research Area: Cancer
Solubility: DMSO : 100 mg/mL (ultrasonic)/H2O : 50 mg/mL (ultrasonic)
Target: Estrogen Receptor/ERR
English
Deutsch
